BDTX-1535 has demonstrated preliminary efficacy in patients with EGFR-mutant NSCLC who progressed on an EGFR TKI, with an overall response rate of 36% in the entire cohort and 42% in those with known EGFR C797S resistance mutation (44). Here, EGFR is linked to non-small cell lung carcinoma.